Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Metabolomics & Genetics Study Update

Samples Collected and Shared with a New Collaborator

Dr. Robert Naviaux
Dr. Oliver Fiehn

We are happy to announce that OMF and Scientific Advisory Board member Dr. Robert Naviaux at University of California, San Diego (UCSD), are now collaborating with Director Oliver Fiehn, PhD and his team at the West Coast Metabolomics Center (WCMC), University of California, Davis (UCD).

Metabolomics Validation Study update from Dr. Naviaux:
“We have exceeded our original goal of 110 samples. We have collected 72 samples from females (36 CFS + 36 Controls), and 54 samples from males (28 CFS and 26 Controls). The total in-house is 126 samples. This is a 50% increase in the size of the study from our 84 samples in study #1.”

The aims of the OMF Metabolomics Validation Study are:
1. Biological replication
2. Analytical replication

From UCSD: The biological replication will come from the metabolomic analysis of the independent cohort of patients with ME / CFS using the mass spec methods developed at UCSD as in the first paper. All patients have been collected and testing has commenced. This will take 4-6 months (hopefully sooner).

From UCD: The analytical replication will come from a replicate analysis of the same samples using similar mass spectometry methods running the same tests by Dr. Oliver Fiehn’s team at UCD – OMF has funded this study as well and it will commence in March.

The results from UCD will be compared to the first and second metabolomics study and all should be completed by July. This testing will be blinded without reviewing results from Dr Naviaux’s validation study until completed. Dr. Fiehn will receive de-identified samples and will be using the same methodology. Each test that is tested within Dr Naviaux’s study will be tested in this study on a similar Mass Spectrometer platform.

To support this revolutionary research, please donate today.

About the UC Davis Team:
Director Oliver Fiehn and his team at the West Coast Metabolomics Center (WCMC) are committed to provide research and services conducting research in metabolomic method developments and biomedical applications. Professor Fiehn and his team pioneered developments and applications in metabolomics since 1998 with over 220 publications to date. Professor Fiehn specifically focuses on lipids and primary metabolism in cancer, cardiovascular diseases, diabetes, nutrition and metabolic syndrome projects. The WCMC is dedicated to provide further standardization and higher content in biochemical information through automatic annotation of metabolites and by using a range of chemical and biochemical database identifiers with every report we generate.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.


In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.


The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.


About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.


Heather Ah San

Development and Communications Manager